Evolution of GLP-1-Based Therapeutics The therapeutic use of GLP-1RAs has evolved significantly, offering various formulations that provide different efficacy, administration routes, and dosing flexibility [19] [20]
The Australia GLP-1 receptor agonist market size accounted for USD 570.49 million in 2025 and is predicted to increase from USD 652.07 million in 2026 to approximately USD 2,117.46 million by 2035, expanding at a CAGR of 14.01% from 2026 to 2035
It was demonstrated that GLP-1 brain administration elevated the circulating concentrations of the adrenocorticotropic hormone (ACTH) and corticosterone and also enhanced anxiety in behavioral measurements [75]
This hormone: Helps your pancreas release insulin Slows digestion and stomach emptying Reduces appetite and food noise Lowers blood sugar Signals fullness to your brain Originally developed to manage type 2 diabetes, GLP-1s like Ozempic, Wegovy, Mounjaro, and Zepbound have exploded in popularity for their weight loss benefitssometimes to the tune of 1520% total body weight reduction
10.1002/dmrr.2413 61
A search of ClinicalTrials.gov reveals few dedicated studies examining GLP-1 or GIP/GLP-1 agents specifically for rheumatoid arthritis treatment
.png&w=128&q=75)
